Angel News

Angel News

Back to Homepage

14th September 2018

Archangels leads £1.3m fund raise for MGB Biopharma

A novel anti-bacterial agent which has been developed in Scotland by MGB Biopharma for the treatment of Clostridium difficile infections, is to enter Phase II clinical trials following a newly-completed £1.3m fund raise from existing and new investors, supplementing a £2.7m grant awarded earlier this year by Innovate UK.


Register / Login now to read full story

In order to read the full story we need you to be registered with us, please click the links below to login or register.

Login / Register

Add a comment:




Enter the characters in the image shown:

Back to Homepage